Your browser doesn't support javascript.
loading
Establishing a core outcome set for mucopolysaccharidoses (MPS) in children: study protocol for a rapid literature review, candidate outcomes survey, and Delphi surveys.
Howie, Alison H; Tingley, Kylie; Inbar-Feigenberg, Michal; Mitchell, John J; Butcher, Nancy J; Offringa, Martin; Smith, Maureen; Angel, Kim; Gentle, Jenifer; Wyatt, Alexandra; Campeau, Philippe M; Chan, Alicia; Chakraborty, Pranesh; El Turk, Farah; Mamak, Eva; Mhanni, Aizeddin; Skidmore, Becky; Sparkes, Rebecca; Stockler, Sylvia; Potter, Beth K.
Afiliação
  • Howie AH; School of Epidemiology and Public Health, University of Ottawa, Room 101, 600 Peter Morand Crescent, Ottawa ON, Canada, Ottawa, ON, K1G 5Z3, Canada.
  • Tingley K; School of Epidemiology and Public Health, University of Ottawa, Room 101, 600 Peter Morand Crescent, Ottawa ON, Canada, Ottawa, ON, K1G 5Z3, Canada.
  • Inbar-Feigenberg M; The Hospital for Sick Children, Toronto, ON, Canada.
  • Mitchell JJ; McGill University Health Centre, Montreal, QC, Canada.
  • Butcher NJ; Child Health Evaluative Sciences, The Hospital for Sick Children Research Institute, Toronto, ON, Canada.
  • Offringa M; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Smith M; The Hospital for Sick Children, Toronto, ON, Canada.
  • Angel K; Child Health Evaluative Sciences, The Hospital for Sick Children Research Institute, Toronto, ON, Canada.
  • Gentle J; Department of Pediatrics, University of Toronto, Toronto, ON, Canada.
  • Wyatt A; Patient Partner, Canadian Organization for Rare Disorders, Ottawa, ON, Canada.
  • Campeau PM; Canadian MPS Society, Vancouver, BC, Canada.
  • Chan A; Patient/Family Partner, Vancouver, BC, Canada.
  • Chakraborty P; Canadian MPS Society, Vancouver, BC, Canada.
  • El Turk F; Department of Pediatrics, CHU Sainte-Justine and Université de Montréal, Montreal, QC, Canada.
  • Mamak E; Department of Medical Genetics, University of Alberta, Edmonton, AB, Canada.
  • Mhanni A; Children's Hospital of Eastern Ontario, Ottawa, ON, Canada.
  • Skidmore B; Department of Pediatrics, University of Ottawa, Ottawa, ON, Canada.
  • Sparkes R; McGill University Health Centre, Montreal, QC, Canada.
  • Stockler S; Department of Pediatrics, CHU Sainte-Justine and Université de Montréal, Montreal, QC, Canada.
  • Potter BK; Department of Psychology, The Hospital for Sick Children, Toronto, ON, Canada.
Trials ; 22(1): 816, 2021 Nov 17.
Article em En | MEDLINE | ID: mdl-34789302
ABSTRACT

BACKGROUND:

Mucopolysaccharidoses (MPS) are a group of inherited metabolic diseases characterized by chronic, progressive multi-system manifestations with varying degrees of severity. Disease-modifying therapies exist to treat some types of MPS; however, they are not curative, underscoring the need to identify and evaluate co-interventions that optimize functioning, participation in preferred activities, and quality of life. A Canadian pediatric MPS registry is under development and may serve as a platform to launch randomized controlled trials to evaluate such interventions. To promote the standardized collection of patient/family-reported and clinical outcomes considered important to patients/families, health care providers (HCPs), and policymakers, the choice of outcomes to include in the registry will be informed by a core outcome set (COS). We aim to establish a patient-oriented COS for pediatric MPS using a multi-stakeholder approach.

METHODS:

In step 1 of the six-step process to develop the COS, we will identify relevant outcomes through a rapid literature review and candidate outcomes survey. A two-phase screening approach will be implemented to identify eligible publications, followed by extraction of outcomes and other pre-specified data elements. Simultaneously, we will conduct a candidate outcomes survey with children with MPS and their families to identify outcomes most important to them. In step 2, HCPs experienced in treating patients with MPS will be invited to review the list of outcomes generated in step 1 and identify additional clinically relevant outcomes. We will then ask patients/families, HCPs, and policymakers to rate the outcomes in a set of Delphi Surveys (step 3), and to participate in a subsequent consensus meeting to finalize the COS (step 4). Step 5 involves establishing a set of outcome measurement instruments for the COS. Finally, we will disseminate the COS to knowledge users (step 6).

DISCUSSION:

The proposed COS will inform the choice of outcomes to include in the MPS registry and, more broadly, promote the standardized collection of patient-oriented outcomes for pediatric MPS research. By involving patients/families from the earliest stage of the research, we will ensure that the COS will be relevant to those who will ultimately benefit from the research. TRIAL REGISTRATION PROSPERO CRD42021267531 , COMET.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Avaliação de Resultados em Cuidados de Saúde / Mucopolissacaridoses Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies / Systematic_reviews Aspecto: Patient_preference Limite: Child / Humans País/Região como assunto: America do norte Idioma: En Revista: Trials Assunto da revista: MEDICINA / TERAPEUTICA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Avaliação de Resultados em Cuidados de Saúde / Mucopolissacaridoses Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies / Systematic_reviews Aspecto: Patient_preference Limite: Child / Humans País/Região como assunto: America do norte Idioma: En Revista: Trials Assunto da revista: MEDICINA / TERAPEUTICA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Canadá
...